Q3 2025 Grifols SA Earnings Call Transcript
Key Points
- Grifols SA (GRFS) reported a year-over-year revenue increase of 7.7%, reaching €5.5 billion, with a like-for-like growth of 10.5% after adjustments.
- The company's adjusted EBITDA for the third quarter was €482 million, contributing to a year-to-date adjusted EBITDA of €1,358 million, up 11.2% and 17.3% like-for-like.
- Free cash flow pre-M&A and pre-dividends improved significantly, reaching €188 million year-to-date, marking a €257 million improvement from the previous year.
- Grifols SA (GRFS) achieved a nearly 1 times improvement in its leverage ratio, which now stands at 4.2 times, reflecting strong financial discipline.
- The company is on track to launch Fibergen in Europe by the end of 2025 and in the US in the first half of 2026, with ongoing FDA applications for congenital fibrinogen deficiency.
- Grifols SA (GRFS) faces exchange rate headwinds impacting revenue and EBITDA levels, although natural hedges have mitigated effects on leverage and free cash flow.
- The company is experiencing pricing pressure in China for its albumin products due to government-imposed cost controls, leading to a contraction in sales.
- The US launch of fibrinogen for acquired fibrinogen deficiency has been delayed to build additional clinical evidence, potentially affecting market entry timing.
- There are potential non-cash adjustments anticipated in Q4, which could impact the carrying value of certain projects, although not affecting future EBITDA or free cash flow growth.
- The weakening US dollar has posed a significant headwind, impacting revenue and EBITDA, although it remains broadly neutral at the net income and free cash flow levels.
Hello everyone, my name is Danny Segarra, and I serve as the head of investor relations and sustainability and Vice President at GREs. Welcome to our review of the company's business results for the third quarter of 2025.
Today I'm joined by Griffith's Chief Executive Officer Nat Avia, the President of Biopharma, Roland Vanderer, and Griffith's Chief Financial Officer Rahul Irinabaan.
A few logistics before we get into the details. Today's call will last about an hour, including a Q&A session.
As a reminder, this call is being recorded. You can find additional materials, including today's presentation in the investor relations section of the Griels website at griefels.com.
The transcript and a reply of the webcast will also be available on the investor relations website within 24 hours.
Turning to a slide 2, please note that this presentation includes forward-looking statements regarding, among other things, the company's future operating and financial performance,
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
